AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23253774 — intervention group
Group type: COMPARATOR
Intervention: Continuous low-dose antibiotic treatment (625 mg amoxicillin/clavulanic acid once daily until stent removal)
Number of subjects: 95
Study 21296338 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention program
Number of subjects: 0
Study 21296338 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 19583075 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (ISO)
Number of subjects: 15
Study 19583075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine‐midazolam‐fentanyl total intravenous anesthesia (TIVA)
Number of subjects: 15
Study 16732095 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.05-0.6 mg/70 kg
Number of subjects: 0
Study 15307696 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus 15 ml of milkvetch injection (MI) every 12 hrs for 14 days
Number of subjects: 40
Study 15307696 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 40
Study 10835440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/h nimodipine (low-dose)
Number of subjects: 265
Study 10835440 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/h nimodipine (high-dose)
Number of subjects: 265
Study 10835440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 9132212 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 week walking programme (900 kcal week‐1 for total duration, 1161 kcal week‐1 during final six weeks, intensity of 67.8% of maximum oxygen consumption)
Number of subjects: 29
Study 9132212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 8262843 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (70 Gy/35 fractions/7 weeks)
Number of subjects: 42
Study 8262843 — intervention group
Group type: COMPARATOR
Intervention: Concomitant boost technique (75 Gy/40 fractions/6 weeks)
Number of subjects: 42
Study 8262843 — intervention group
Group type: COMPARATOR
Intervention: Nodal status
Number of subjects: 42
Study 4087694 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 14
Study 29415593 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥1 serving of fish per week
Number of subjects: 852
Study 29415593 — intervention group
Group type: COMPARATOR
Intervention: <1 serving of fish per week
Number of subjects: 852
Study 29133080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 933
Study 26911633 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine 300 mg/d
Number of subjects: 60
Study 26911633 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine 900 mg/d
Number of subjects: 60
Study 26911633 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 25185672 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin with lansoprazole
Number of subjects: 100
Study 25185672 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin mono-therapy
Number of subjects: 100
Study 22268920 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily for 60 days
Number of subjects: 21
Study 22268920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 21034177 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily
Number of subjects: 72
Study 21034177 — intervention group
Group type: COMPARATOR
Intervention: Travoprost 0.004% once daily
Number of subjects: 72
Study 17951479 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic-supplemented hypoallergenic formula (8 g/L scGOS/lcFOS)
Number of subjects: 0
Study 17951479 — intervention group
Group type: COMPARATOR
Intervention: Placebo-supplemented hypoallergenic formula (8 g/L maltodextrin)
Number of subjects: 0
Study 15876285 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily therapy with stavudine prolonged-release capsule (PRC)
Number of subjects: 43
Study 15876285 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily regimens based on stavudine immediate release or zidovudine
Number of subjects: 43
Study 12530019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum/Treosulfan (PT)
Number of subjects: 519
Study 12530019 — intervention group
Group type: COMPARATOR
Intervention: Cisplatinum/Cyclophosphamide (PC)
Number of subjects: 519
Study 9800147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 250 mg
Number of subjects: 7
Study 9800147 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 500 mg
Number of subjects: 7
Study 9800147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7634805 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg i.v. over 30 mins)
Number of subjects: 10
Study 2501516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopy performed 3 months after initial transurethral resection
Number of subjects: 0
Study 2501516 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of tumors at presentation (single or multiple)
Number of subjects: 0
Study 2501516 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up procedures based on prognosis groups
Number of subjects: 0
Study 325598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial lidocaine (2% and 1%)
Number of subjects: 25
Study 325598 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 25
Study 31354106 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxed α-levels (up to 0.1) in series of trials
Number of subjects: 0
Study 31354106 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analysis with futility rule
Number of subjects: 0
Study 31354106 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analysis for efficacy
Number of subjects: 0
Study 31354106 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-arm trials
Number of subjects: 0
Study 31354106 — intervention group
Group type: COMPARATOR
Intervention: Two-arm trials
Number of subjects: 0
Study 30919151 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 500‐mg tablet of levofloxacin without enema (Group A)
Number of subjects: 420
Study 30919151 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 500‐mg tablet of levofloxacin plus enema (Group B)
Number of subjects: 420
Study 30919151 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐day levofloxacin orally plus enema (Group C)
Number of subjects: 420
Study 30919151 — intervention group
Group type: COMPARATOR
Intervention: Group A (500 mg levofloxacin without enema)
Number of subjects: 420
Study 30919151 — intervention group
Group type: COMPARATOR
Intervention: Group B (500 mg levofloxacin plus enema)
Number of subjects: 420
Study 29282143 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (12-month course, weekly)
Number of subjects: 0
Study 29282143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26703278 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.4% (Group A)
Number of subjects: 120
Study 26703278 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bromfenac 0.09% (Group B)
Number of subjects: 120
Study 26703278 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1% (Group C)
Number of subjects: 120
Study 26703278 — intervention group
Group type: COMPARATOR
Intervention: No NSAIDs (Group D, control)
Number of subjects: 120
Study 23909049 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy patch tests with aeroallergens (1 x skin prick tests concentration)
Number of subjects: 29
Study 23909049 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE and skin prick tests
Number of subjects: 29
Study 21764428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 8122
Study 21764428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8122
Study 18843180 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser therapy 20 min a day for 3 months with a 650‐nm, 5‐mW soft laser (group L)
Number of subjects: 60
Study 18843180 — intervention group
Group type: COMPARATOR
Intervention: Dummy device (group C)
Number of subjects: 60
Study 16959660 — intervention group
Group type: EXPERIMENTAL
Intervention: ArginMax for women
Number of subjects: 108
Study 16959660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 15340661 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus Methotrexate (MTX)
Number of subjects: 58
Study 15340661 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 58
Study 10932510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stone-former group (external oblique muscle)
Number of subjects: 202
Study 10932510 — intervention group
Group type: COMPARATOR
Intervention: Control group I (external oblique muscle)
Number of subjects: 202
Study 10932510 — intervention group
Group type: COMPARATOR
Intervention: Control group II (rectus abdominis muscle)
Number of subjects: 202
Study 10932510 — intervention group
Group type: COMPARATOR
Intervention: Control group III (quadriceps femoris muscle)
Number of subjects: 202
Study 9008503 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen
Number of subjects: 88
Study 9008503 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen
Number of subjects: 88
Study 9008503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 8388307 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1500 mg/day)
Number of subjects: 25
Study 8388307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3802699 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal plus 75 ml 70% sorbitol
Number of subjects: 9
Study 3802699 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal
Number of subjects: 9
Study 3802699 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study 30755472 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA through a helmet
Number of subjects: 10
Study 30755472 — intervention group
Group type: COMPARATOR
Intervention: Pressure support through a face mask
Number of subjects: 10
Study 29217375 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg ZPIV vaccine
Number of subjects: 67
Study 29217375 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 67
Study 27018060 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored 12-week home-based exercise programme of treadmill interval training and strength exercises
Number of subjects: 26
Study 27018060 — intervention group
Group type: COMPARATOR
Intervention: Waiting Control Group (usual care)
Number of subjects: 26
Study 24797657 — intervention group
Group type: EXPERIMENTAL
Intervention: IQP-GC-101
Number of subjects: 91
Study 24797657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 22702906 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacytarabine 2000 mg/m² per day continuously i.v. during days 1‐5 every 3 weeks
Number of subjects: 61
Study 22702906 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 61
Study 20036549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32-34 degrees C)
Number of subjects: 148
Study 20036549 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 148
Study 17662114 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 720
Study 17662114 — intervention group
Group type: COMPARATOR
Intervention: Expectant management for spontaneous delivery
Number of subjects: 720
Study 15330404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg/day)
Number of subjects: 18
Study 15330404 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 18
Study 11220425 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam administered 30 min preoperatively
Number of subjects: 73
Study 11220425 — intervention group
Group type: COMPARATOR
Intervention: 20 mg tenoxicam administered at induction of anesthesia
Number of subjects: 73
Study 9426331 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim initiated on day 4
Number of subjects: 46
Study 9426331 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim initiated on day 6
Number of subjects: 46
Study 9426331 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim initiated on day 8
Number of subjects: 46
Study 8032065 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustanon 250 (250 mg, 1 ml)
Number of subjects: 30
Study 8032065 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 ml)
Number of subjects: 30
Study 2891992 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 143
Study 2891992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 29751823 — intervention group
Group type: EXPERIMENTAL
Intervention: KENKOJISEICHI group - 90-minute sessions twice per week for 6 months
Number of subjects: 83
Study 29751823 — intervention group
Group type: COMPARATOR
Intervention: Educational control group - 120-minute educational classes during the 6-month trial period
Number of subjects: 83
Study 27543592 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach service for adult patients with AKI, delivered via a phone call, with or without a visit to the primary clinician, aiming at rapidly establishing the aetiology, correcting reversible causes and conducting further appropriate investigation.
Number of subjects: 0
Study 27543592 — intervention group
Group type: COMPARATOR
Intervention: Good standard care for patients with AKI in the control hospital and its area.
Number of subjects: 0
Study 24519387 — intervention group
Group type: EXPERIMENTAL
Intervention: ET + ZOL (4 mg every 3 months for 2 years)
Number of subjects: 70
Study 24519387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 70
Study 20449757 — intervention group
Group type: COMPARATOR
Intervention: Healthy women
Number of subjects: 21
Study 20449757 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D Poor Control (HbA1c ≥ 7%)
Number of subjects: 21
Study 20449757 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D Good Control (HbA1c < 7%)
Number of subjects: 21
Study 20449757 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D (both subgroups)
Number of subjects: 21
Study 20919668 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel
Number of subjects: 218
Study 20919668 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 218
Study 18937897 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (GI) diets
Number of subjects: 0
Study 18937897 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index (GI) diets
Number of subjects: 0
Study 16870076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a commercial NRL extract
Number of subjects: 26
Study 16870076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16870076 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 26
Study 12811692 — intervention group
Group type: EXPERIMENTAL
Intervention: imatinib (Glivec, Novartis, Switzerland)
Number of subjects: 72
Study 10980221 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflutren (5 or 10 microl/kg)
Number of subjects: 211
Study 10980221 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 211
Study 8784400 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual anastomosis
Number of subjects: 154
Study 8784400 — intervention group
Group type: COMPARATOR
Intervention: Mechanical anastomosis
Number of subjects: 154
Study 1290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation
Number of subjects: 64
Study 1290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 64
Study 1290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic induction
Number of subjects: 64
Study 1290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 64
Study 6539253 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-treated semen
Number of subjects: 60
Study 6539253 — intervention group
Group type: COMPARATOR
Intervention: Control (semen without caffeine)
Number of subjects: 60
Study 31597690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine hesitancy screening (15-item PACV survey)
Number of subjects: 156
Study 31597690 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo survey items only)
Number of subjects: 156
Study 29214336 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTA) injections within 5 days of primary closure
Number of subjects: 30
Study 29214336 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 30
Study 27530285 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg droperidol
Number of subjects: 41
Study 27530285 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg droperidol
Number of subjects: 41
Study 27530285 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg + 10 mg droperidol (repeated at 15 min)
Number of subjects: 41
Study 27530285 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg and 10 mg)
Number of subjects: 41
Study 24334641 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) 16.6 ± 5.2 mg/d for 3.6 ± 2.2 years
Number of subjects: 43
Study 24334641 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 43
Study 23146366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional barbed suture
Number of subjects: 60
Study 23146366 — intervention group
Group type: COMPARATOR
Intervention: Traditional sutures
Number of subjects: 60
Study 23146366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 19631391 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz left prefrontal rTMS
Number of subjects: 0
Study 19631391 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz left prefrontal rTMS
Number of subjects: 0
Study 17999224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive anxiety intensity
Number of subjects: 12
Study 17999224 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic anxiety intensity
Number of subjects: 12
Study 17999224 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-confidence intensity
Number of subjects: 12
Study 17999224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive directional anxiety
Number of subjects: 12
Study 17999224 — intervention group
Group type: EXPERIMENTAL
Intervention: Direction
Number of subjects: 12
Study 14671681 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of 500 mg ASA and 30 mg PSE
Number of subjects: 18
Study 14671681 — intervention group
Group type: COMPARATOR
Intervention: Preliminary formulation of ASA and PSE
Number of subjects: 18
Study 11033842 — intervention group
Group type: EXPERIMENTAL
Intervention: bb genotype sarcoidosis patients
Number of subjects: 0
Study 11033842 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR genotypes
Number of subjects: 0
Study 11033842 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR gene polymorphism
Number of subjects: 0
Study 8993754 — intervention group
Group type: EXPERIMENTAL
Intervention: IMREGR-1 treatment
Number of subjects: 0
Study 1458046 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Neuroelectric Therapy (NET)
Number of subjects: 43
Study 1458046 — intervention group
Group type: COMPARATOR
Intervention: Placebo NET
Number of subjects: 43
Study 6386019 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free morphine 2 mg in saline
Number of subjects: 150
Study 6386019 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 150
Study 6386019 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free morphine 4 mg in saline
Number of subjects: 150
Study 30782586 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment of COPD exacerbation
Number of subjects: 0
Study 30782586 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment for COPD exacerbation
Number of subjects: 0
Study 28602711 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-Aid (DA)
Number of subjects: 26
Study 28602711 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SoC)
Number of subjects: 26
Study 25759150 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (exposed to a general fatigue task)
Number of subjects: 112
Study 25759150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to a general fatigue task)
Number of subjects: 112
Study 23724696 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy on PC 6 (Neiguan) and additional acupuncture points (PC 4, HT 7, PC 7, PC 5, PC 3, CV 17, CV 6, BL 15, L 20, BL 17, BL 23, BL 18, HT 5, ST 36)
Number of subjects: 0
Study 23724696 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug regimen (e.g., Nitroglycerine, Isosorbide mononitrate, Propranolol)
Number of subjects: 0
Study 20546501 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV co-infection
Number of subjects: 3143
Study 20546501 — intervention group
Group type: COMPARATOR
Intervention: HIV mono-infection
Number of subjects: 3143
Study 18799510 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic contrast echocardiography (TTCE)
Number of subjects: 299
Study 18799510 — intervention group
Group type: COMPARATOR
Intervention: Chest high-resolution computed tomography (HRCT)
Number of subjects: 299
Study 16118648 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with high saturated fatty acid (SFA) content
Number of subjects: 18
Study 16118648 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with low saturated fatty acid (SFA) content
Number of subjects: 18
Study 16118648 — intervention group
Group type: COMPARATOR
Intervention: Control (fat-exclusion lunch, snack, and dinner)
Number of subjects: 18
Study 16446341 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/gemcitabine (PCG)
Number of subjects: 324
Study 16446341 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin (PC)
Number of subjects: 324
Study 11322160 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified functional obstacle course (FOC)
Number of subjects: 36